Michael Buege
Clinical Assistant Professor, College of PharmacyAssociate Member, University of Illinois Cancer Center, Translational Oncology Program
Contact
Office Phone:
Email:
Related Sites:
Teaching and Supervision Heading link
Evidence-Based Medicine (PHAR 440), 2/13/2023 – 4/28/2023
Evidence-Based Medicine (PHAR 440), 2/13/2023 – 4/28/2023
Selected Publications
Villa, Diego, Jiang, Aixiang, Visco, Carlo, Crosbie, Nicola, McCulloch, Rory, Buege, Michael J, Kumar, Anita, Bond, David A, Paludo, Jonas, Maurer, Matthew J, Thanarajasingam, Gita, Lewis, Katharine Louise, Cheah, Chan Yoon, Baech, Joachim, Galaly, Tarec C El, Kugathasan, Laveniya, Scott, David W, Gerrie, Alina S, Lewis, David. (2023). Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma. Blood Advances, 7, (16), 4576-4585. doi:10.1182/bloodadvances.2023009804.
Sawalha, Yazeed, Goyal, Subir, Switchenko, Jeffrey M, Romancik, Jason T, Kamdar, Manali, Greenwell, Irl Brian, Hess, Brian T, Isaac, Krista M, Portell, Craig A, Garcia, Alex V Mejia, Goldsmith, Scott R, Grover, Natalie S, Riedell, Peter A, Karmali, Reem, Burkart, Madelyn, Buege, Michael, Akhtar, Othman S, Torka, Pallawi, Kumar, Anita, Hill, Brian T, Kahl, Brad S, Cohen, Jonathon B. (2023). A Multicenter Analysis of the Outcomes with Venetoclax in Patients with Relapsed Mantle Cell Lymphoma. Blood Advances, 7, (13), 2983-2993. doi:10.1182/bloodadvances.2022008916.
Buege, Michael J, Drill, Esther, Horwitz, Steven M, LeVoir, Andréa, Pak, Terry, Peterson, Tim J, Dao, Phuong H, Matasar, Matthew J. (2023). Low incidence of cardiotoxicity in patients with non‐Hodgkin lymphoma receiving EPOCH after prior anthracycline exposure. European Journal Of Haematology, 111, (1), 96-102. doi:10.1111/ejh.13971.
King, Amber, Land, Josiah, Liu, Dazhi, Peterson, Tim, Reiss, Samantha, Vadakkel, Grashma, Eng, Stephen, Pak, Terry, Daukshus, Nicole, Spatz, Krisoula, LeVoir, Andrea, Buege, Michael, Weis, Taylor, Gutierrez, Jillian. (2022). Cancer Pharmacology. Pocket Oncology.
Pak, Terry K, Dixon, Brianne N, Buege, Michael J, Dao, Phuong H, Leary, Megan H, Jarrett, Joy C, Duggan, Tara A, Caron, Philip, Falchi, Lorenzo, Hamlin, Paul, Hamilton, Audrey, Matasar, Matthew J, Moskowitz, Alison, Noy, Ariela, Owens, Colette N, Von Keudell, Gottfried, Younes, Anas, Zelenetz, Andrew D, Kumar, Anita. (2022). Successful implementation of outpatient R ± DHAX (rituximab, dexamethasone, oxaliplatin, cytarabine) for select patients with lymphoma: a single-center experience. Leukemia & Lymphoma, 63, (4), 876-884. doi:10.1080/10428194.2021.2002318.
Buege, Michael J, Dao, Phuong H, Drill, Esther, LeVoir, Andréa, Pak, Terry, Peterson, Tim J, Straus, David J. (2021). IVAC With or Without Rituximab for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas: Real-World Experience in the Modern Era. Clinical Lymphoma Myeloma & Leukemia, 21, (12), 873-878. doi:10.1016/j.clml.2021.07.024.
Yerram, Prakirthi, Thackray, Jennifer, Modelevsky, Lisa R, Land, Josiah D, Reiss, Samantha N, Spatz, Krisoula H, Levoir, Andrea C, Pak, Terry K, Dao, Phuong H, Buege, Michael J, Derespiris, Lauren M, Lau, Carmen, Orozco, Jennifer S, Boparai, Manpreet, Koranteng, Lauren A, Reichert, Kate E, Yan, Shirley Q, Daukshus, Nicole P, Mathew, Sherry, Buie, Larry W, Tizon, Richard F, Freeswick, Scott, Liu, Dazhi, Harnicar, Stephen. (2021). Outpatient clinical pharmacy practice in the face of COVID-19 at a cancer center in New York City. Journal of Oncology Pharmacy Practice, 27, (2), 389-394. doi:10.1177/1078155220987625.
Buege, Michael J, Kumar, Anita, Dixon, Brianne N, Tang, Laura A, Pak, Terry, Orozco, Jennifer, Peterson, Tim J, Maples, Kathryn T. (2020). Management of Mantle Cell Lymphoma in the Era of Novel Oral Agents. Annals of Pharmacotherapy, 54, (9), 879-898. doi:10.1177/1060028020909117.
Peterson, Tim J, Orozco, Jennifer, Buege, Michael. (2020). Selinexor: A First-in-Class Nuclear Export Inhibitor for Management of Multiply Relapsed Multiple Myeloma. Annals of Pharmacotherapy, 54, (6), 577-582. doi:10.1177/1060028019892643.
Professional Leadership
Oral Chemotherapy Collaborative, Hematology Oncology Pharmacy Association, 6/1/2023 - 5/31/2025
Education
Degrees:
PharmD, Drake University, United States, 2016
Postgraduate Training:
PGY1 Pharmacy Residency, The University of Texas MD Anderson Cancer Center, United States, 2017
PGY2 Oncology Pharmacy Residency, The University of Texas MD Anderson Cancer Center, United States, 2018
Licensures and Certifications
Board Certified Oncology Pharmacist, Board of Pharmacy Specialties, Date Not Set - Present